[The PORTEC-3 trial for high-risk endometrial cancer: impact of molecular classification on prognosis and benefit from adjuvant therapy].

PORTEC-3-Studie für Endometriumkarzinome mit hohem Risiko: Auswirkungen der molekularen Klassifizierung auf die Prognose und den Nutzen einer adjuvanten Therapie.

Publisher: Urban & Vogel Country of Publication: Germany NLM ID: 8603469 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-099X (Electronic) Linking ISSN: 01797158 NLM ISO Abbreviation: Strahlenther Onkol Subsets: MEDLINE

Original Publication: [München] : Urban & Vogel, [c1986-

Endometrial Neoplasms*; Combined Modality Therapy ; Female ; Humans ; Prognosis

Comment on: Lancet Oncol. 2018 Mar;19(3):295-309. (PMID: 29449189)

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB et al (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19:295–309. (PMID: 10.1016/S1470-2045(18)30079-2)
Leon-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, Nijman HW et al (2020) Molecular classification of the PORTEC‑3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 38:3388–3397. (PMID: 10.1200/JCO.20.00549)
Raffone A, Travaglino A, Mascolo M, Carbone L, Guida M, Insabato L, Zullo F (2019) TCGA molecular groups of endometrial cancer: pooled data about prognosis. Gynecol Oncol 155:374–383. (PMID: 10.1016/j.ygyno.2019.08.019)
Marnitz S, Waltar T, Köhler C, Mustea A, Schömig-Markiefka B (2020) The brave new world of endometrial cancer: future implications for adjuvant treatment decisions. Strahlenther Onkol 196:963–972. (PMID: 10.1007/s00066-020-01632-w)
Marnitz S, Walter T, Schömig-Markiefka B, Engler T, Kommoss S, Brucker SY (2020) A modern approach to endometrial carcinoma: Will molecular classification improve precision medicine in the future? Cancers (Basel) 12(9):2577. (PMID: 10.3390/cancers12092577)
Creutzberg CL, Nout RA, Lybeert ML, Warlam-Rodenhuis CC, Jobsen JJ, Mens JW, Lutgens LC et al (2011) Fifteen-year radiotherapy outcomes of the randomized PORTEC‑1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 81:e631–e638. (PMID: 10.1016/j.ijrobp.2011.04.013)
Ko E, Funk M, Brewster W (2011) Have PORTEC 1 and GOG 99 changed practice patterns in the United States? Gynecol Oncol 121:S100–S100. (PMID: 10.1016/j.ygyno.2010.12.239)
Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens L, van der Steen-Banasik EM et al (2018) Ten-year results of the PORTEC‑2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 119:1067–1074. (PMID: 10.1038/s41416-018-0310-8)
Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, Mannel RS et al (2019) Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol 37:1810–1818. (PMID: 10.1200/JCO.18.01575)
Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM et al (2019) Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 380:2317–2326. (PMID: 10.1056/NEJMoa1813181)
Marnitz S, Köhler C, Gharbi N, Kunze S, Jablonska K, Herter J (2018) Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions? Strahlenther Onkol 194(11):965–974. (PMID: 10.1007/s00066-018-1339-6)
Waltar T, Marnitz S (2020) Clinical implications of the PORTEC‑3 trial for the treatment of high-risk endometrial cancer. Strahlenther Onkol 196:410–413. (PMID: 10.1007/s00066-020-01592-1)

Date Created: 20210106 Date Completed: 20210505 Latest Revision: 20210505

20221213

10.1007/s00066-020-01735-4

33403442